1Y Target$123.29Near-term target
5Y Target$121.30Compound horizon
10Y Target$154.83Long-dated conviction
FCF$4.2bTTM · 03/26BFCF $4.2b — solid, comfortably covers operations and capital return · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+64.9%TTM YoYARevenue +64.9% — hypergrowth, top decile
D/E0.22A-D/E 0.22 — conservative leverage, strong balance sheet
P/E13.3xB+P/E 13.3 — at or below S&P median, reasonable
PEG0.78A-PEG 0.78 — strong; Lynch's preferred zone
Why now
Gold · market cap $45.8b. Down 30% from 52-week high of $129.14 — deep drawdown territory. Revenue growing +65% — in hypergrowth territory. PEG 0.78 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $123.29 (implying +36% upside).
Moat
Net margin 31% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 43% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 121% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Reserve-replacement treadmill — every barrel or ounce extracted has to be replaced through exploration or acquisition; underspending on replacement reserves shows up in production declines 2-3 years out.
Horizon
1-3 yr $123.29 (7-analyst consensus) — multiple re-rating thesis requires a catalyst. 5 yr $121.30 at ~6% CAGR — dividend + buyback compounding. 10 yr $154.83 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.